Acute Lung Injury Market Size to Outstrip $741.98Mn by 2028 Growth Projections at 4.7% CAGR During 2021 to 2028 COVID Impact and Global Analysis by TheInsightPartners.com New York, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Acute Lung Injury Market: Key InsightsAccording to our new research study on "Acute Lung Injury Market to 2028 – Global Analysis and Forecast – by...

Angion Provides Corporate Update and Reports First Quarter 2021 Financial Results UNIONDALE, N.Y., May 17, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...

Angion Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results UNIONDALE, N.Y., March 30, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...

Angion Completes Enrollment in Phase 2 Study of ANG-3777 for Acute Lung Injury in Patients with COVID-19 Associated Pneumonia UNIONDALE, N.Y., March 25, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ: ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of...

P2D Bioscience Receives NIH Funding to Develop Drugs for Lung Disease CINCINNATI, OH and MUMBAI, INDIA--(Marketwire - Jul 19, 2011) - P2D Bioscience (P2D, Inc.), a pharmaceutical development company, announced today that the company has received a $320,000 grant from...